Asparaginase for acute lymphoblastic leukemia and lymphoblastic lymphoma.

Drugs Today (Barc)

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St.John's University, Queens, New York City, New York, USA.

Published: June 2022

Acute lymphoblastic leukemia (ALL) is a neoplastic disease characterized by the malignant proliferation of lymphoid cells in the blood and bone marrow. It accounts for approximately 75% of childhood leukemia. Lymphoblastic lymphoma (LBL) is a type of non-Hodgkin's lymphoma characterized by rapid growth and highly aggressive characteristics that occurs most commonly in adolescents and young adults. Asparaginase is primarily used to treat patients with ALL or LBL. Because allergic reactions occur in patients treated with bacterial-derived asparaginase, it is important to develop an alternative asparaginase preparation for patients allergic to asparaginase. Recombinant asparaginase -rywn (JZP-458) is a recombinant asparaginase that uses a novel expression platform in the production process. JZP-458 has the same amino acid sequence as -derived asparaginase (ERW) and its in vitro activity is similar to that of ERW. JZP-458 is highly efficacious in patients allergic to asparaginase. Data from a phase I clinical trial indicated that following the intramuscular or intravenous administration of JZP-458 to volunteers, serum asparaginase activity ≥ 0.1 IU/mL was observed in 100% of the volunteers 72 hours after administration. In this review, we summarize the mechanism of action and the related research data obtained with JZP-458 for the treatment of ALL or LBL.

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2022.58.6.3413459DOI Listing

Publication Analysis

Top Keywords

asparaginase
10
acute lymphoblastic
8
lymphoblastic leukemia
8
leukemia lymphoblastic
8
lymphoblastic lymphoma
8
patients allergic
8
allergic asparaginase
8
recombinant asparaginase
8
jzp-458
5
asparaginase acute
4

Similar Publications

L-asparaginase (asparagine amidohydrolase) contributes to 40% of the total enzyme demands worldwide and is one-third of the global requirement as an anti-cancerous drug in treating acute lymphocytic leukemia (ALL), a type of leukemia. This protein breaks down L-asparagine into aspartic acid and ammonia those involved in ALL, rely on for growth and survival. Both non-recombinant and recombinant L-asparaginase can be produced by bacteria when a suitable substrate and method (solid-state fermentation (SSF) or submerged fermentation (SmF) which are techniques to grow microorganisms under controlled conditions), is provided.

View Article and Find Full Text PDF

L-Asparaginase CLEAs were prepared utilizing sodium tripolyphosphate (TPP) as a crosslinker (TA-CLEA). Under optimized conditions (pH 3, 0.3% TPP concentration, and a crosslinking time of 1 h), an 85% activity recovery was achieved.

View Article and Find Full Text PDF

Biocatalytic enzymes in food packaging, biomedical, and biotechnological applications: A comprehensive review.

Int J Biol Macromol

January 2025

State Key Laboratory of Geohazard Prevention and Geoenvironment Protection, Chengdu University of Technology, Chengdu 610059, China. Electronic address:

The increasing environmental concerns and health risks associated with synthetic chemicals have driven the demand for sustainable and eco-friendly solutions. Biocatalysis, employing enzymes or whole cells as biocatalysts, has emerged as a powerful alternative. This review provides a comprehensive analysis of the applications of biocatalytic enzymes in food packaging, biomedical sciences, and biotechnology.

View Article and Find Full Text PDF

The present study explores the microbial community associated with the industrially important red seaweed Gracilaria dura to determine the diversity and biotechnological potential through culture and metagenomics approaches. In the first part of the investigation, we isolated and characterized 75 bacterial morphotypes, with varied colony characteristics and metabolic diversity from the wild seaweed. Phylogenetic analysis identified isolates in Proteobacteria, Firmicutes, and Actinobacteria, with Bacillus sp.

View Article and Find Full Text PDF

l-Asparaginase (l-ASNase) catalyzes the hydrolysis of l-asparagine, leading to its depletion and subsequent effects on the cellular proliferation and survival. In contrast to normal cells, malignant cells that lack asparagine synthase are extremely susceptible to asparagine deficiency. l-ASNase has been successfully employed in treating pediatric leukemias and non-Hodgkin lymphomas; however, its usage in adult patients and other types of cancer is limited due to significant side effects and drug resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!